NCT03470311View on ClinicalTrials.gov

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

June 14, 2022

Study Completion Date

November 30, 2022

Conditions
Severe Prednisone Dependent Eosinophilic Asthma
Interventions
BIOLOGICAL

Benralizumab

30mg in 1mL pre-filled syringe

BIOLOGICAL

Placebo

Matched placebo (1mL) in pre-filled syringe

Trial Locations (1)

L8N 4A6

Firestone Institute for Respiratory Health, Research - St. Joseph's Healthcare, Hamilton

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

St. Joseph's Healthcare Hamilton

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

McMaster University

OTHER